🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Happy to share our latest report (Scientific Reports) on smartly edited "Bespoken Antibody Releasing (BAR)"-B cells! Congratulations to Marine, Natsuko, Jenny, Yannic and thanks to all the collaborators... rdcu.be/dVoD5

📢New paper alert📢 Published in Journal of Clinical Oncology, it brings hope of MRD assessment in the blood of myeloma patients using NGF and mass spec, which we called peripheral residual disease = PRD #mmsm Carmen González Díaz-Cano Noemi Puig PETHEMA Clínica Universidad de Navarra Cima Universidad de Navarra ascopubs.org/doi/pdf/10.120…

KDM6A regulates immune response genes in multiple myeloma ashpublications-org.insb.bib.cnrs.fr/blood/article-…

Dupéré-Richer and colleagues reveal a role for KDM6A in myeloma immune evasion and open the door for epigenome targeting to restore immune surveillance and tumor recognition in myeloma. KDM6A controls immunogenicity in MM ashpublications.org/blood/article/…

Transient EZH2 suppression by Tazemetostat during in vitro expansion maintains T-cell stemness and improves adoptive T-cell therapy aacrjournals.org/cancerimmunolr…

"5th Annual Meeting on Advances on Nuclear Topology and 3D Chromatin Architecture in Cancer" A virtual meeting announcement for people interested in chromosome organization and cancer. To register use the QR code in the flyer attached, or use this link: nyulangone.zoom.us/webinar/regist…

B cell heterogeneity in cancer comes of age dlvr.it/TFV3Gj

Our new study Springer Nature @MolecularCancer reveals epigenetic markers at birth linked to pediatric leukemia! This breakthrough offers hope for early diagnosis & targeted therapy. See how we’re tracing cancer origins back to birth! #PediatricCancer link.springer.com/10.1186/s12943…

We are pleased to inform you that the meeting “From Genome Instability to Cancer: A tribute to Angelos Constantinou” that will take place in Carry-Le-Rouet from March 10th to March 13th 2025 is now open for registration on the link: tribute2angelos.fr/page/home/

The hallmarks of cancer immune evasion dlvr.it/TG8BBS

sBCMA, surface antigen density, effector-to-target ratio, and TCE dose collectively mediate primary refractoriness to anti-BCMA TCE. ow.ly/V5mT50Uv0QH #immunobiologyandimmunotherapy #lymphoidneoplasia #multiplemyeloma

#Myeloma Paper of the Day: Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in #Waldenstrom macroglobulinemia display immune suppressive activity through a direct T cell inhibition: pubmed.ncbi.nlm.nih.gov/39695096/. #wmsm

Online Now: Plasma cell and cancer stem cell crosstalk in glioblastoma dlvr.it/TH8rGC

EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function dlvr.it/THLx62

Happy to share the last paper of the group: Targeting Transcription-Replication Conflicts using G-quadruplexes sta... sciencedirect.com/science/articl… InstituteHumGenetics CHU de Montpellier Université de Montpellier Institut universitaire de France (IUF) #myeloma Many thanks to all the co-authors and sponsors.

After Musk & stoping this platform for a while, Here I am: Sharing My first thread in bluesky :) about our new preprint of the lab. Music ON! New method: #SNUPR #Bortezomib #MultipleMyeloma Share 🙏 bsky.app/profile/rafaja… Julien Paul Gigan Moreaux Jérôme Stephane Rocchi CNRS Provence et Corse

#Myeloma Paper of the Day: Study of germline predisposition in myeloma finds candidates in 9.1% of sporadic & 18% of familial cases; implicated genes were DIS3, EP300, KDM1A, USP45, ATM, BRCA1/2, CHEK2, PMS2, POT1, PRF1, TP53, BRIP1, EP300, & FANCM: pubmed.ncbi.nlm.nih.gov/39845416/. #mmsm

Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets pubmed.ncbi.nlm.nih.gov/39855192/

#Myeloma Paper of the Day: Targeting the ABCD1-ACOX1-MET/IGF1R axis suppresses myeloma, in part by promoting the accumulation of very long chain fatty acid-containing cerebrosides, revealing a specific metabolic vulnerability: pubmed.ncbi.nlm.nih.gov/39885295/. #mmsm

Trispecific antibodies in myeloma! Sham Mailankody (Memorial Sloan Kettering Cancer Center) presents on JNJ-796353222 and multi-antigen targeting at #iwCART25. A new approach to overcoming resistance in myeloma! 💥🧬 #Myeloma #TrispecificAntibodies